Immuneering Corporation Increase (Decrease) in Other Operating Assets
Immuneering Corporation (IMRX) reported Increase (Decrease) in Other Operating Assets of -$5.44 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingAssets · last filed 2026-08-05
- Immuneering Corporation increase (decrease) in other operating assets for the quarter ending 2026-06-30 was -$6.00, a 100.01% decline year-over-year.
- Immuneering Corporation increase (decrease) in other operating assets for the quarter ending 2026-03-31 was -$5.43K.
- Immuneering Corporation increase (decrease) in other operating assets for the quarter ending 2025-12-31 was -$311.40K.
- Immuneering Corporation increase (decrease) in other operating assets for the quarter ending 2025-09-30 was -$348.79K, a 615.25% decline year-over-year.
- Immuneering Corporation increase (decrease) in other operating assets for fiscal 2025 was -$1.11M, a 526.36% decline from fiscal 2024.
- Immuneering Corporation increase (decrease) in other operating assets for fiscal 2024 was $261.34K, a 10.11% decline from fiscal 2023.
- Immuneering Corporation increase (decrease) in other operating assets for fiscal 2023 was $290.74K, a 19.28% decline from fiscal 2022.
- Immuneering Corporation increase (decrease) in other operating assets for fiscal 2022 was $360.20K.
| Period end | Increase (Decrease) in Other Operating Assets 3 month | Increase (Decrease) in Other Operating Assets 6 month | Increase (Decrease) in Other Operating Assets 9 month | Increase (Decrease) in Other Operating Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$6.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$5.44K 10-Q · filed 2026-08-05 | -$316.84K derived: sum of 3 quarters · filed 2026-08-05 | -$665.63K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$5.43K 10-Q · filed 2026-05-15 | -$316.83K derived: sum of 2 quarters · filed 2026-05-15 | -$665.62K derived: sum of 3 quarters · filed 2026-05-15 | -$570.78K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$311.40K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | -$660.19K derived: sum of 2 quarters · filed 2026-03-06 | -$565.34K derived: sum of 3 quarters · filed 2026-08-05 | -$1.11M 10-K · filed 2026-03-06 |
| 2025-09-30 | -$348.79K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$253.95K derived: sum of 2 quarters · filed 2026-08-05 | -$802.85K 10-Q · filed 2025-11-12 | -$802.85K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $94.84K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$454.06K 10-Q · filed 2026-08-05 | -$454.06K derived: sum of 3 quarters · filed 2026-08-05 | -$386.37K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$548.90K 10-Q · filed 2026-05-15 | -$548.90K derived: sum of 2 quarters · filed 2026-05-15 | -$481.21K derived: sum of 3 quarters · filed 2026-05-15 | -$257.56K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $67.69K derived: sum of 2 quarters · filed 2026-03-06 | $291.34K derived: sum of 3 quarters · filed 2026-03-06 | $261.34K 10-K · filed 2026-03-06 |
| 2024-09-30 | $67.69K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $291.34K derived: sum of 2 quarters · filed 2025-11-12 | $261.34K 10-Q · filed 2025-11-12 | $552.08K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $223.64K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $193.64K 10-Q · filed 2025-08-13 | $484.39K derived: sum of 3 quarters · filed 2025-08-13 | $484.39K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$30.00K 10-Q · filed 2025-05-05 | $260.74K derived: sum of 2 quarters · filed 2025-05-05 | $260.74K derived: sum of 3 quarters · filed 2025-05-05 | $260.74K derived: sum of 4 quarters · filed 2025-05-05 |
| 2023-12-31 | $290.74K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $290.74K derived: sum of 2 quarters · filed 2025-03-20 | $290.74K derived: sum of 3 quarters · filed 2025-03-20 | $290.74K 10-K · filed 2025-03-20 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | $4.08K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | $4.08K derived: sum of 3 quarters · filed 2024-08-06 | $372.75K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-07 | $4.08K derived: sum of 2 quarters · filed 2024-05-07 | $372.75K derived: sum of 3 quarters · filed 2024-05-07 | $372.75K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $4.08K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $372.75K derived: sum of 2 quarters · filed 2024-03-01 | $372.75K derived: sum of 3 quarters · filed 2024-03-01 | $360.20K 10-K · filed 2024-03-01 |
| 2022-09-30 | $368.67K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $368.67K derived: sum of 2 quarters · filed 2023-11-09 | $356.12K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$12.55K 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | -$12.55K 10-Q · filed 2023-05-04 | |||
| 2021-06-30 | $946.05K 10-Q · filed 2022-08-10 | |||
| 2020-12-31 | $14.33K 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |